Abstract
Complement-dependent cytotoxicity against melanoma cells was demonstrated with a microassay in sera from melanoma patients. The response was tumor-specific and histologic type-specific since 16 out of 52 (30%) melanoma patient sera taken before surgery reacted against melanoma cells, whereas 3 out of 43 (7%) control sera, collected from patients with unrelated tumors and from cancer-free individuals, were positive. The serum activity correlated with the clinical stage of the disease since it was detected in 15 out of 40 patients with stage I and II tumors and in 1 of the 12 patients in stage III. Twelve melanoma patients, clinically tumor-free for to 4 years after surgery, showed no humoral cytotoxicity. A follow-up study of 13 melanoma patients revealed that the cytotoxicity appeared 7-10 days after radical removal of the tumor and that it disappeared if there was no recurrence. The histologic type-specificity was further tested by assaying sera from 16 melanoma and 10 breast-cancer patients simultaneously on both melanoma and breast-cancer cells; a positive reaction was observed in 6 cases of melanoma and in 5 of breast cancer on homologous cells only, in 1 case on the opposite type of cells, and in 3 cases on both types of ...Continue Reading
References
Mar 1, 1975·European Journal of Immunology·C Müller, C Sorg
Jun 15, 1974·International Journal of Cancer. Journal International Du Cancer·D G Jose, R Seshadri
Jan 1, 1973·Tissue Antigens·K K MittalP I Terasaki
Jan 15, 1971·International Journal of Cancer. Journal International Du Cancer·I HellströmG A Warner
Sep 15, 1974·International Journal of Cancer. Journal International Du Cancer·E T BloomS A Brosman
Mar 15, 1972·International Journal of Cancer. Journal International Du Cancer·H O SjögrenK E Hellström
Aug 1, 1974·Journal of the National Cancer Institute·G W Wood, R F Barth
May 15, 1972·International Journal of Cancer. Journal International Du Cancer·J P FaucaultC Lecacheux
Oct 1, 1973·Transplantation·K K MittalP I Terasaki
Mar 15, 1973·International Journal of Cancer. Journal International Du Cancer·I HellströmH O Sjögren
Jul 15, 1973·International Journal of Cancer. Journal International Du Cancer·E T BloomG Trempe
Nov 1, 1973·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·U VeronesiG Balzarini
Apr 1, 1974·Journal of the National Cancer Institute·R F IrieD L Morton
Sep 6, 1969·British Medical Journal·M G LewisP Alexander
Dec 18, 1970·Science·W C Wood, D L Morton
Citations
May 20, 1977·Zeitschrift Für Krebsforschung Und Klinische Onkologie. Cancer Research and Clinical Oncology·R W Baldwin
Sep 24, 2004·Annals of Surgical Oncology·Eddy C HsuehDonald L Morton
Nov 15, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·E C Hsueh
Dec 15, 1975·International Journal of Cancer. Journal International Du Cancer·G T Stevenson, D J Laurence
Jan 1, 1982·Critical Reviews in Clinical Laboratory Sciences·T E Carey
Jun 24, 2010·Critical Reviews in Oncology/hematology·K KamposiorasN Pavlidis
May 1, 1982·Clinical Immunology and Immunopathology·P B DentD P Singal
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chris C LeeDonald L Morton
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eddy C HsuehDonald L Morton
May 15, 1982·Cancer·P B DentD P Singal
Jul 1, 1979·Cancer·H BiranJ L Moake
May 3, 2000·Annals of Surgical Oncology·E C HsuehD L Morton
Nov 27, 1998·Annals of Surgical Oncology·E C HsuehD L Morton
Apr 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J EmbletonR W Baldwin